Drug: Tasigna (nilotinib)
Indication: Chronic myeloid leukemia
Approval Date: October 29, 2007
Scoop: Novartis has won FDA approval of Tasigna for patients with chronic myeloid leukemia who are resistant to Gleevec. Tasigna works by inhibiting the proliferation of cells containing an abnormal chromosome called the Philadelphia chromosome.
Novartis wins FDA approval for Tasigna. Report